Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ropinirole dosing for up to 28 days · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ropinirole dosing for up to 28 days | DRUG | - |
Inclusion: * Patients and subjects between 18-79 years old. * End stage renal patients who are consistently receiving dialysis for a minimum of 3.5 hours, three times per week, with hemodialysis blood flow rates of \>200mL/min may be eligible to enter the study. * Patients must also have systolic b...
Ropinirole is a small molecule drug developed by GSK plc for Restless Legs Syndrome, a neurological condition. It has been studied in a Phase 1 clinical trial in patients with end stage renal disease undergoing hemodialysis. The trial, NCT00422994, completed with 48 participants.
Ropinirole targets the dopamine receptors DRD2, DRD3, and DRD4, acting as an agonist. This means it stimulates these receptors, which are involved in neurological signaling. The drug is being developed for Restless Legs Syndrome, a condition where dopamine dysfunction is implicated.
Ropinirole is being developed by GSK plc, a pharmaceutical company traded under the ticker GSK. GSK is responsible for the clinical development of this small molecule drug for Restless Legs Syndrome.
Ropinirole is in Phase 1 clinical development. A Phase 1 trial, NCT00422994, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
Ropinirole has been studied in one clinical trial: NCT00422994, titled 'A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole.' This Phase 1 trial was completed, enrolled 48 participants, and took place in the United States and United Kingdom.